Skip to main content
Ongoing trials:


AtTEnd   Codice EudraCT: 2018-001072-37 / ID: NCT03603184

AtTEnd: Atezolizumab Trial in Endometrial cancer. Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.

The study involved centers in Italy, Switzerland, the United Kingdom, Spain, Germany, Austria, Japan, Australia/New Zealand, Korea and Taiwan, for a total of 95 clinical centers. The enrollment period began in October 2018 and was closed in January 2022, when the sample size required by the protocol was reached. 551 patients were randomized.

The study is currently active, in the follow-up phase. The final Progression Free Survival (PFS) analysis was performed during August 2023. The results of the PFS analysis will be presented by the Principal Investigator (Prof. Nicoletta Colombo) during the Congress of the European Society For Medical Oncology (ESMO) in Madrid, at the end of October 2023.

Synopsis(click to view PDF)

Updates(click to view updates)


NEWTON    Codice EudraCT: 2018-003736-77 / ID: NCT03891576

NEWTON: NEW dosing mainTenance therapy Ovarian caNcer. A multicenter, open-label phase II trial of a new customized dosing (rational adjustment of dose to reduce adverse reactions “radar” dosing) of Niraparib as maintenance therapy in platinum sensitive ovarian, fallopian tube or primary peritoneal recurrent cancer patients.

Multicenter and international trial involving a total of 12 clinical centers: 9 centers in Italy and 3 in Germany. So far, 79 patients have been enrolled, out of a planned total of 105 patients. The study is currently enrolling.

Synopsis(click to view PDF)


LEPRE    Codice EudraCT: 2020-003066-39 / ID: NCT05601700

LEPRE: Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer.


IOLANTHE   EU number: 2022-502242-27-00 / Protocol number: IRFMN-0VA-8542

IOLANTHE: a phase IV trial to confirm the efficacy of Olaparib in combination with Bevacizumab as maintenance frontline treatment of HRD positive ovarian tumours

Synopsis (click to view PDF)

Closed trials:


INOVATYON    Codice EudraCT: 2010-022949-17 / ID: NCT01379989

Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum

Synopsis(click to view PDF)

INOVATYON Article (click to view the article)



BAROCCO    Codice EudraCT: 2016-003964-38 / ID: NCT03314740

The BAROCCO study: Best Approach in Resistant-Ovarian-Cancer with-Cediranib-Olaparib. An Italian multicenter randomized phase II study of weekly paclitaxel vs. Cediranib-Olaparib with continuous schedule vs. Cediranib-Olaparib with intermittent schedule in patients with platinum resistant high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Synopsis(click to view PDF)

BAROCCO (click to view PDF)